Biochemical prevention and treatment of viral infections – A new paradigm in medicine for infectious diseases
AUTOR(ES)
Le Calvez, Hervé
FONTE
BioMed Central
RESUMO
For two centuries, vaccination has been the dominating approach to develop prophylaxis against viral infections through immunological prevention. However, vaccines are not always possible to make, are ineffective for many viral infections, and also carry certain risk for a small, yet significant portion of the population. In the recent years, FDA's approval and subsequent market acceptance of Synagis, a monoclonal antibody indicated for prevention and treatment of respiratory syncytial virus (RSV) has heralded a new era for viral infection prevention and treatment. This emerging paradigm, herein designated "Biochemical Prevention and Treatment", currently involves two aspects: (1) preventing viral entry via passive transfer of specific protein-based anti-viral molecules or host cell receptor blockers; (2) inhibiting viral amplification by targeting the viral mRNA with anti-sense DNA, ribozyme, or RNA interference (RNAi). This article summarizes the current status of this field.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=535550Documentos Relacionados
- Passive Immunity in Prevention and Treatment of Infectious Diseases
- Screening of some plants used in the Brazilian folk medicine for the treatment of infectious diseases
- Hunter's Tropical Medicine and emerging infectious diseases
- Vaccination in the prevention of infectious respiratory diseases in adults
- HIF-1alpha and infectious diseases: a new frontier for the development of new therapies